Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 1070-1074

  Chen, Xiaobing ^a,b   Cao, Xinguang ^b   Dong, Wenjie ^c   Xia, Microgene ^d   Luo, Suxia ^b   Fan, Qingxia ^a   Xie, Jing ^e  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Henan Tumor Hospital   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cystatin M; Gastric cancer; Hypermethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYSTATIN; CYSTATIN M;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METHYLATION; MOLECULAR MECHANICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; SURVIVAL TIME;

BASE SEQUENCE; CARCINOMA; CELL LINE, TUMOR; CYSTATIN M; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 73149115274     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.022     Document Type: Article

References (24)

1. Zhang J., Shridhar R., Dai Q., Song J., Barlow S.C., Yin L., Sloane B.F., Miller F.R., Meschonat C., Li B.D., Abreo F., and Keppler D. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. 64 (2004) 6957-6964
2. Shridhar R., Zhang J., Song J., Booth B.A., Kevil C.G., Sotiropoulou G., Sloane B.F., and Keppler D. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23 (2004) 2206-2215
3. Vigneswaran N., Wu J., Nagaraj N., James R., Zeeuwen P., and Zacharias W. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion. Life Sci. 78 (2006) 898-907
4. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett. 235 (2006) 159-176
5. Lin H.J., Zuo T., Lin C.H., Kuo C.T., Liyanarachchi S., Sun S., Shen R., Deatherage D.E., Potter D., Asamoto L., Lin S., Yan P.S., Cheng A.L., Ostrowski M.C., and Huang T.H. Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res. 68 (2008) 10257-10266
6. Song J., Jie C., Polk P., Shridhar R., Clair T., Zhang J., Yin L., and Keppler D. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Biochem. Biophys. Res. Commun. 340 (2006) 175-182
7. Kioulafa M., Balkouranidou I., Sotiropoulou G., Kaklamanis L., Mavroudis D., Georgoulias V., and Lianidou E.S. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int. J. Cancer 125 (2009) 2887-2892
8. Zeeuwen P.L., van Vlijmen-Willems I.M., Hendriks W., Merkx G.F., and Schalkwijk J. A null mutation in the cystatin M/E gene of ichq mice causes juvenile lethality and defects in epidermal cornification. Hum. Mol. Genet. 11 (2002) 2867-2875
9. Ai L., Kim W.J., Kim T.Y., Fields C.R., Massoll N.A., Robertson K.D., and Brown K.D. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 66 (2006) 7899-7909
10. Kim T.Y., Zhong S., Fields C.R., Kim J.H., and Robertson K.D. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 66 (2006) 7490-7501
11. Sinicrope F.A., Ruan S.B., Cleary K.R., Stephens L.C., Lee J.J., and Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55 (1995) 237-241
12. Kim J.S., Kim H., Shim Y.M., Han J., Park J., and Kim D.H. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 25 (2004) 2165-2171
13. Rivenbark A.G., Livasy C.A., Boyd C.E., Keppler D., and Coleman W.B. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp. Mol. Pathol. 83 (2007) 188-197
14. Veena M.S., Lee G., Keppler D., Mendonca M.S., Redpath J.L., Stanbridge E.J., Wilczynski S.P., and Srivatsan E.S. Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer 47 (2008) 740-754
15. Pulukuri S.M., Gorantla B., Knost J.A., and Rao J.S. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene 28 (2009) 2829-2838
16. Zeeuwen P.L., van Vlijmen-Willems I.M., Olthuis D., Johansen H.T., Hitomi K., Hara-Nishimura I., Powers J.C., James K.E., op den Camp H.J., Lemmens R., and Schalkwijk J. Evidence that unrestricted legumain activity is involved in disturbed epidermal cornification in cystatin M/E deficient mice. Hum. Mol. Genet. 13 (2004) 1069-1079
17. Vigneswaran N., Wu J., Muller S., Zacharias W., Narendran S., and Middleton L. Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells - a preliminary study. Pathol. Res. Pract. 200 (2005) 753-762
18. Schagdarsurengin U., Pfeifer G.P., and Dammann R. Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 26 (2007) 3089-3094
19. Rodenhiser D.I., Andrews J., Kennette W., Sadikovic B., Mendlowitz A., Tuck A.B., and Chambers A.F. Epigenetic mapping, functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res. 10 (2008) R62
20. Vauhkonen H., Vauhkonen M., Sajantila A., Sipponen P., and Knuutila S. Characterizing genetically stable and unstable gastric cancers by microsatellites and array comparative genomic hybridization. Cancer Genet. Cytogenet. 170 (2006) 133-139
21. D'Adda T., Keller G., Bordi C., and Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab. Invest. 79 (1999) 671-677
22. Anlauf M., Perren A., and Kloppel G. Gastrin cell hyperplasia associated with duodenal MEN1-related gastrinomas: histopathology and genetics. Verh Dtsch. Ges. Pathol. 91 (2007) 320-329
23. Srivatsan E.S., Chakrabarti R., Zainabadi K., Pack S.D., Benyamini P., Mendonca M.S., Yang P.K., Kang K., Motamedi D., Sawicki M.P., Zhuang Z., Jesudasan R.A., Bengtsson U., Sun C., Roe B.A., Stanbridge E.J., Wilczynski S.P., and Redpath J.L. Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. Oncogene 21 (2002) 5631-5642
24. Stenman G., Astrom A.K., Roijer E., Sotiropoulou G., Zhang M., and Sager R. Assignment of a novel cysteine proteinase inhibitor (CST6) to 11q13 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 76 (1997) 45-46